Literature DB >> 26282174

Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia.

Laura Patrussi1, Nagaja Capitani1, Veronica Martini2, Marco Pizzi3, Valentina Trimarco2, Federica Frezzato2, Filippo Marino3, Gianpietro Semenzato2, Livio Trentin2, Cosima T Baldari4.   

Abstract

Lymphocyte trafficking is orchestrated by chemokine and sphingosine 1-phosphate (S1P) receptors that enable homing and egress from secondary lymphoid organs (SLO). These receptors undergo rapid internalization and plasma membrane recycling to calibrate cellular responses to local chemoattractants. Circulating chronic lymphocytic leukemia (CLL) cells display an abnormal increase in the surface levels of the homing receptors CCR7 and CXCR4 concomitant with low S1P receptor 1 (S1P1) expression. In this study, we investigated the role of receptor recycling on CXCR4/CCR7 surface levels in CLL cells and addressed the impact of quantitative alterations of these receptors and S1P1 on the ability of leukemic cells to accumulate in SLOs. We show that recycling accounts, to a major extent, for the high levels of surface CXCR4/CCR7 on CLL cells. In addition, increased expression of these receptors, together with S1P1 deficiency, is detectable not only in circulating leukemic cells, but also in SLOs of CLL patients with lymphoadenopathy. We further provide evidence that ibrutinib, a Btk inhibitor that promotes mobilization of leukemic cells from SLOs, normalizes the imbalance between CXCR4/CCR7 and S1P1. Taken together, our results highlight the relevance of chemokine and S1P receptor recycling in CLL pathogenesis and clinical outcome. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26282174     DOI: 10.1158/0008-5472.CAN-15-0986

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

Review 2.  S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy.

Authors:  Narges Rostami; Afshin Nikkhoo; Amir Ajjoolabady; Gholamreza Azizi; Mohammad Hojjat-Farsangi; Ghasem Ghalamfarsa; Bahman Yousefi; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Mol Diagn Ther       Date:  2019-08       Impact factor: 4.074

3.  Clinical and functional impact of recurrent S1PR1 mutations in mantle cell lymphoma.

Authors:  Agata M Wasik; Chenglin Wu; Larry Mansouri; Richard Rosenquist; Qiang Pan-Hammarström; Birgitta Sander
Journal:  Blood Adv       Date:  2018-03-27

4.  p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes.

Authors:  Laura Patrussi; Nagaja Capitani; Francesca Cattaneo; Noemi Manganaro; Alessandra Gamberucci; Federica Frezzato; Veronica Martini; Andrea Visentin; Pier Giuseppe Pelicci; Mario M D'Elios; Livio Trentin; Gianpietro Semenzato; Cosima T Baldari
Journal:  Oncogene       Date:  2018-01-12       Impact factor: 9.867

Review 5.  C-C Chemokine Receptor 7 in Cancer.

Authors:  Colin A Bill; Christopher M Allen; Charlotte M Vines
Journal:  Cells       Date:  2022-02-14       Impact factor: 6.600

6.  p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF-κB.

Authors:  Vanessa Tatangelo; Gioia Boncompagni; Nagaja Capitani; Ludovica Lopresti; Noemi Manganaro; Federica Frezzato; Andrea Visentin; Livio Trentin; Cosima T Baldari; Laura Patrussi
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

Review 7.  Exit Strategies: S1P Signaling and T Cell Migration.

Authors:  Audrey Baeyens; Victoria Fang; Cynthia Chen; Susan R Schwab
Journal:  Trends Immunol       Date:  2015-12       Impact factor: 16.687

8.  Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.

Authors:  Prithviraj Bose; Varsha V Gandhi; Michael J Keating
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-11       Impact factor: 4.481

Review 9.  Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Authors:  M Pizzi; M Boi; F Bertoni; G Inghirami
Journal:  Leukemia       Date:  2016-06-08       Impact factor: 11.528

10.  Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia.

Authors:  Stéphane Saint-Georges; Maude Quettier; Marouane Bouyaba; Stéphanie Le Coquil; Vanessa Laurienté; Lionel Guittat; Vincent Lévy; Florence Ajchenbaum-Cymbalista; Nadine Varin-Blank; Christine Le Roy; Dominique Ledoux
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.